Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects

Authors: Pfützner, Andreas; Weber, Matthias M; Forst, Thomas

Source: Expert Opinion on Pharmacotherapy, Volume 8, Number 12, August 2007 , pp. 1985-1998(14)

Buy & download fulltext article:

Price: $99.00 plus tax (Refund Policy)

Abstract:

Pioglitazone, a member of the PPAR-γ agonist drug family, has been demonstrated to improve both metabolic and vascular insulin resistance when applied to patients with Type 2 diabetes mellitus. The drug is well tolerated with fluid retention and weight gain being the most frequently described side effects. The observed effects (e.g., improvements in glucose and lipid metabolism, improvements of endothelial function and microcirculation, reduction of surrogate markers of atherosclerosis and inflammation and an improvement in hypertension) have made pioglitazone one of the frequently prescribed antidiabetic drugs in the US and Europe. Several trials have shown its potency to reduce carotid intima-media thickness, and outcome studies with pioglitazone have shown its potential to delay the progression of Type 2 diabetes and atherosclerosis and even reduce cardiovascular mortality. The purpose of this review is to provide an overview about recently published clinical results with pioglitazone. They underline the value of this drug when used alone or in combination with other antidiabetic drugs for a successful management of Type 2 diabetes mellitus.

Keywords: cardiovascular disease; insulin resistance; intima-media thickness; pioglitazone; Type 2 diabetes mellitus

Document Type: Drug Evaluation

DOI: http://dx.doi.org/10.1517/14656566.8.12.1985

Publication date: 2007-08-01

More about this publication?